COSCIENS Q3 Loss Widens, Revenue Rises
Cocrystal Pharma reported a third-quarter net loss of $3.44 million, up from $2.05 million a year earlier; its net loss for the first nine months was $8.91 million, compared with $6.41 million. The company also completed dosing in a Phase 1b norovirus challenge study of CDI-988, which tested the drug for prevention and treatment in healthy adults. No serious adverse events were reported, and preliminary efficacy results are expected in late 2026.
How it spread
Claim check
What each side asserts, disputes — or leaves out entirely.
Where do you land?
Whose framing of this story rings truest to you?







